On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

[1]  Uma Yasothan,et al.  Brentuximab vedotin , 2012, Nature Reviews Drug Discovery.

[2]  R. Abraham,et al.  Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells , 2012, Molecular Cancer Therapeutics.

[3]  D. Shah,et al.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  Harvey Wong,et al.  Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response , 2012, Clinical Cancer Research.

[5]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[6]  C. J. O’Donnell,et al.  Investigational antibody drug conjugates for solid tumors , 2011, Expert opinion on investigational drugs.

[7]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Saileta Prabhu,et al.  Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.

[9]  J. Gibbs.  Prediction of Exposure–Response Relationships to Support First-in-Human Study Design , 2010, The AAPS Journal.

[10]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Sliwkowski,et al.  Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Lynn McFadyen,et al.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Donald E. Mager,et al.  Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems , 2010, The AAPS Journal.

[14]  Honghui Zhou,et al.  Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look , 2009, Journal of clinical pharmacology.

[15]  Peter Lloyd,et al.  The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. , 2009, Current opinion in biotechnology.

[16]  Eugene Wong,et al.  Mathematical modeling of liver metastases tumour growth and control with radiotherapy , 2008, Physics in medicine and biology.

[17]  E. Giné,et al.  Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study , 2008 .

[18]  G. Tortora,et al.  The use of xenograft models for the selection of cancer treatments with the EGFR as an example. , 2008, Critical reviews in oncology/hematology.

[19]  Steven W. Martin,et al.  The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.

[20]  M Rocchetti,et al.  Predicting the active doses in humans from animal studies: a novel approach in oncology. , 2007, European journal of cancer.

[21]  H. McAneney,et al.  Investigation of various growth mechanisms of solid tumour growth within the linear-quadratic model for radiotherapy , 2007, Physics in medicine and biology.

[22]  Larry Norton,et al.  Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. , 2005, The oncologist.

[23]  P. Houghton,et al.  Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. , 2004, European journal of cancer.

[24]  L. Kèlland,et al.  Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. , 2004, European journal of cancer.

[25]  Paolo Magni,et al.  Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.

[26]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  R. Kerbel.  Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved , 2003, Cancer biology & therapy.

[28]  Siddharth J. Advant,et al.  Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design , 2002, AAPS PharmSci.

[29]  Marky Pitts,et al.  A guide to the new ARENA/OLAW IACUC guidebook. , 2002, Lab animal.

[30]  Gerrit Borchard,et al.  Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures , 2002, AAPS PharmSci.

[31]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[32]  N. Ferrara,et al.  Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans , 1999, Toxicologic pathology.

[33]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[34]  Evelyn D. Lobo,et al.  Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro , 2008, AAPS PharmSci.

[35]  Damon L. Meyer,et al.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.